Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine

AIDS

Volumn 19, Issue 14, 2005, Pages 1495-1499

  Chokephaibulkit, Kulkanya ^a   Plipat, Nottasorn ^a   Cressey, Tim R ^b,c   Frederix, Koen ^d   Phongsamart, Wanatpreeya ^a   Capparelli, Edmund ^e   Kolladarungkri, Teera ^a   Vanprapar, Nirun ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c CHIANG MAI UNIVERSITY   (Thailand)

^d Médicines Sans Frontières   (Thailand)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Children; Fixed dose combination; GPO VIR; Nevirapine; Pharmacokinetics

Indexed keywords

CD4 ANTIGEN; LAMIVUDINE; NEVIRAPINE; STAVUDINE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PLASMA HALF LIFE; PRIORITY JOURNAL; TABLET FORMULATION;

EID: 25844490364     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000183625.97170.59     Document Type: Article

References (17)

1. Working Group on Antiretroviral Therapy and Medical Management of HIV-infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Maryland, MD: Centers for Disease Control and Prevention; November 30, 2004. http://AIDSinfo.nih.gov, /guidelines/pediatric/ PED_032405.pdf; access 20 April, 2005.
2. World Health Organization. Scaling up Antiretroviral Therapy in Resource-constrained Settings: Treatment Guidelines for a Public Health Approach: 2003 revision. Geneva: World Health Organization; 2003. http://www.who.int/hiv/pub/prev_care/ en/arvrevision2003en.pdf.pdf; access 19 March, 2005.
3. 3: AIDS Clinical Trials Group Protocol 208. J Infect Dis 1995; 172:1379-1383.
4. Veldkamp AI, Weverling GJ, Lange JM, Montaner JS, Reiss P, Cooper DA, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001; 15:1089-1095.
5. Droste JA, Verweij-van Wissen CP, Burger DM. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8, and nevirapine in human plasma by reversed-phase high-performance liquid chromatography. Ther Drug Monit 2003; 25:393-399.
6. Holland DT, DiFrancesco R, Stone J, Hamzeh F, Connor JD, Morse GD. Quality assurance program for clinical measurement of antiretrovirals: AIDS Clinical Trials Group proficiency testing program for pediatric and adult pharmacology laboratories. Antimicrob Agents Chemother 2004; 48:824-831.
7. Capparelli E, Blanchard S, Aweeka F, Acosta E. Population pharmacokinetics of nevirapine in infants and children: the impact of body size, age, and concomitant therapy. Sixth International Workshop on Clinical Pharmacology of HIV Therapy. Quebec, 2005 [Abstract 37].
8. Beal S, Sheiner L, Boeckmann A. NONMEM User Guide. Hanover, MD: GloboMax LLC; 1994.
9. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171:537-545.
10. de Vries-Sluijs TE, Dieleman JP, Arts D, Huitema AD, Beijnen JH, Schutten M, et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003; 42:599-605.
11. Panel on Clinical Practice for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-infected Adults and Adolescents. Washington, DC: US National Institutes of Health Division of AIDS; 20 October, 2004. http:// AIDSinfo.nih.gov/guidelines/adult/TABLE26_AA_102904.pdf; accessed 19 March, 2005.
12. Cheeseman SH, Havlir D, McLaughlin MM, Greenough TC, Sullivan JL, Hall D, et al. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8:141-151.
13. van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000; 14:F77-F82.
14. Luzuriaga K, Bryson Y, McSherry G, Robinson J, Stechenberg B, Scott G, et al. Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children. J Infect Dis 1996; 174:713-721.
15. Anekthananon T, Ratanasuwan W, Techasathit W, Sonjai A, Suwanagool S. Safety and efficacy of a simplified fixed dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of HIV-infected patients. XV International Conference on AIDS. Bangkok, July 2004 [Abstract TuPe4481].
16. Puthanakit T, Oberdorfer A, Akarathum N, Kanjanavanit S, Wanarit P, Sirisanthana T, et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's national access to antiretroviral program. Clin Infect Dis 2005; 41:100-107.
17. Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers M, Dusek A. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. J Infect Dis 1999; 179:1116-1123.